종목/DGX
Quest Diagnostics Incorporated
Full year 2026 updated guidance: Net revenues $11.78 billion - $11.90 billion (Net revenues increase 6.8% - 7.8%); Reported diluted EPS $9.58 - $9.78; Adjusted diluted EPS $10.63 - $10.83; Cash provided by operations Approximately $1.75 billion; Capital expenditures Approximately $550 million.
아래 내용은 AI 가 8-K Item 2.02 본문과 보도자료(Exhibit 99.x)를 종합해 한국어로 정리한 요약입니다. 핵심 하이라이트·가이던스·운영 코멘트·시장 평가 네 섹션 모두 AI 생성이며, 실제 원문은 EDGAR 링크에서 확인하세요.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 4월 21일 (화) | 2026 Q1 | $2.37 | $2.50 | +5.5% | $2.90B | ▲ 4.4% |
| 12월 1일 (월) | 2025 Q4 | $2.36 | $2.42 | +2.6% | $2.82B | — |
| UNH | 유나이티드헬스 | 364B | +8.9% | 75% (3/4) |
| MRK | 머크 | 281B | +16.0% | 100% (4/4) |
강한 유기적 매출 성장, 조정 및 보고 EPS 증가, 그리고 가이던스 상향은 시장에 긍정적(beat/상향 톤)으로 받아들여질 가능성이 높음. 다만 영업현금흐름은 전년보다 감소했고 매출채권이 증가한 점은 향후 수금 및 현금 전환 리스크로 시장이 주시할 수 있음.
| 9월 1일 (월) | 2025 Q3 | $2.50 | $2.60 | +3.9% | $2.76B | — |
| 6월 1일 (일) | 2025 Q2 | $2.57 | $2.62 | +1.9% | $2.65B | — |